Show simple item record

dc.contributor.authorDi Zazzo, Antonio
dc.contributor.authorRoberti, Gloria
dc.contributor.authorMashaghi, Alireza
dc.contributor.authorAbud, Tulio Batista [UNIFESP]
dc.contributor.authorPavese, Daniela
dc.contributor.authorBonini, Stefano
dc.date.accessioned2020-09-01T13:21:29Z
dc.date.available2020-09-01T13:21:29Z
dc.date.issued2017
dc.identifierhttp://dx.doi.org/10.1089/jop.2016.0117
dc.identifier.citationJournal Of Ocular Pharmacology And Therapeutics. New Rochelle, v. 33, n. 9, p. 670-677, 2017.
dc.identifier.issn1080-7683
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/58302
dc.description.abstractPurpose: Chronic use of topical hypotensive therapies in glaucoma patients leads to chronic inflammation of the ocular surface, which decreases the success rate of long-term glaucoma management. The aim of this study is to evaluate the effect of topical palmitoylethanolamide (PEA) (Defluxa((c))), a well-known anti-inflammatory and analgesic agent, in suppressing the ocular surface inflammation associated with the use of hypotensive eye drops. Methods: In a pilot clinical trial, we enrolled 15 glaucomatous patients who received topical PEA (Defluxa) in addition to the current antiglaucoma drugs, while 15 glaucomatous patients did not receive any additional treatment. At 3 different time points (day 0, 15, and 30), signs of ocular surface involvement, adverse events, visual acuity, and intraocular pressure were assessed. Results: Topical PEA (Defluxa) was effective in increasing the Schirmer test (P<0.05) and the tear film breakup time (T-BUT) (P<0.0001), and improving the conjunctival hyperemia (P<0.0001) by day 30, compared to baseline. Compared to control, by day 15, the conjunctival hyperemia score was significantly decreased in the PEA (Defluxa) group (P<0.01), while the T-BUT and the Schirmer Test achieved a significant improvement by day 30 (P<0.05; P<0.01). Discussion: Our data suggests that topical PEA (Defluxa) is a safe, effective, and generally well-tolerated treatment to prevent or suppress ocular surface inflammation attributable to chronic glaucoma treatment.en
dc.description.sponsorshipMinistry of Health
dc.description.sponsorshipFondazione Roma
dc.format.extent670-677
dc.language.isoeng
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofJournal Of Ocular Pharmacology And Therapeutics
dc.rightsAcesso restrito
dc.subjectpalmitoylethanolamideen
dc.subjectdry eyeen
dc.subjectglaucomaen
dc.subjectinflammationen
dc.subjectocular surfaceen
dc.subjectantiglaucoma drugsen
dc.titleUse of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medicationsen
dc.typeArtigo
dc.description.affiliationFdn GB Bietti, IRCCS, Rome, Italy
dc.description.affiliationLeiden Univ, Leiden Acad Ctr Drug Res, Fac Math & Nat Sci, Leiden, Netherlands
dc.description.affiliationHarvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Boston, MA USA
dc.description.affiliationBasir Eye Hlth Res Ctr, Tehran, Iran
dc.description.affiliationUniv Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil
dc.description.affiliationCampus Biomed Univ, Dept Ophthalmol, Rome, Italy
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil
dc.identifier.doi10.1089/jop.2016.0117
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000413275500004
dc.coverageNew Rochelle
dc.citation.volume33
dc.citation.issue9


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record